Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3-targeting CAR-T cells in advanced hepatocellular carcinoma
NCT05352542Phase 1Terminated
- Start
- May 2022
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of GPC3 Targeting CART Cells in hepatocellular carcinoma (HCC). Primary endpoints: Treatment-Emergent Adverse Events at 2 years and Dose-Limiting Toxicity at 2 years. Started May 2022; status: terminated.
02
Drugs
GPC3 Targeting CART Cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05352542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352542.